Significance Tests for Cancer Screening Trials

DOI10.2307/2531689MaRDI QIDQ3201526zbMATH OpenOpenAlexWikidataFDO

Authors Robert E. Tarone, John J. Gart

Publication date 1989

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.2307/2531689

zbMATH Keywords

score testsufficient statisticPoisson modelsasymptotic relative efficienciesuniformly most powerful unbiased testcancer screening trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Planning clinical trials to evaluate early detection programmes
• Estimating case-fatality reduction from randomized screening trials
• Optimal tests for carcinogenicity in a model with fatal and incidental tumours.
• Estimating Lead Time and Sensitivity in a Screening Program without Estimating the Incidence in the Screened Group
• Probability modeling and statistical inference in periodic cancer screening

Cited in

(6)

• Planning of randomized early detection trials
• A Novel Design for Estimating Relative Accuracy of Screening Tests When Complete Disease Verification Is Not Feasible
• Design and testing for clinical trials faced with misclassified causes of death
• The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing
• Estimating case-fatality reduction from randomized screening trials
• A holistic analysis of Poisson data with application to a trial of selenium and cancer deaths

This page was built for publication: Significance Tests for Cancer Screening Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201526)